Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.53 |
| ▸ | CTSB | P07858 | 9/20 | 0.52 |
| ▸ | CTSL | P07711 | 5/20 | 0.52 |
| ▸ | CTSS | P25774 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5344211 | 0.91 | CTSK (0.54) | CTSKCTSBCTSLCTSS | |
| SCHEMBL6385886 | 0.87 | CTSK (0.47) | CTSKCTSBCTSLCTSS | |
| SCHEMBL6385881 | 0.87 | CTSK (0.47) | CTSKCTSBCTSLCTSS | |
| SCHEMBL6386047 | 0.87 | CTSK (0.47) | CTSKCTSBCTSLCTSS | |
| SCHEMBL5350501 | 0.86 | CTSK (0.57) | CTSKCTSBCTSLCTSS | |
| SCHEMBL5350496 | 0.86 | CTSK (0.57) | CTSKCTSBCTSLCTSSNPC1 | |
| SCHEMBL5365055 | 0.85 | DPP4 (0.50) | CTSKCTSBCTSLCTSS | |
| SCHEMBL5345668 | 0.85 | CTSK (0.43) | CTSKCTSBCTSLCTSS | |
| SCHEMBL6380871 | 0.85 | CTSK (0.47) | CTSKCTSBCTSLCTSSRAB9A | |
| SCHEMBL6380877 | 0.85 | CTSK (0.47) | CTSKCTSBCTSLCTSSRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248949-A1 | Benzamide nitriles | ROCHE PALO ALTO LLC | 2004-12-09 | — | — | US | claimed |
| US-7300934-B2 | Benzamide nitriles | ROCHE PALO ALTO LLC (US) | 2007-11-27 | — | — | US | disclosed |
| US-7300934-B2 | Benzamide nitriles | ROCHE PALO ALTO LLC (US) | 2007-11-27 | — | — | US | disclosed |
| US-7300934-B2 | Benzamide nitriles | ROCHE PALO ALTO LLC (US) | 2007-11-27 | — | — | US | disclosed |
| US-20040248949-A1 | Benzamide nitriles | ROCHE PALO ALTO LLC | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248949-A1 | Benzamide nitriles | CTSK, CTSS, CMA1 | CTSK 1/4885CTSB 5/4885CTSL 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.